Protia Inc. (303360.KQ) stock: key figures, P/E, revenue and dividend
Health Care · South Korea
Protia Inc. financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 10.51 bn KRW | 15.12 bn KRW |
| Gross profit | 6.27 bn KRW | 9.30 bn KRW |
| Operating income | 1.50 bn KRW | 3.72 bn KRW |
| EBIT | 2.34 bn KRW | 4.23 bn KRW |
| Net income | 2.44 bn KRW | 4.47 bn KRW |
| Diluted EPS – continuing operations | 189.65 KRW | 347.23 KRW |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Protia Inc.
Protia Inc. manufactures and sells in vitro diagnostic medical devices in South Korea. It offers allergy, animal diagnosis, autoimmune, antibiotic susceptibility, POCT, cancer, and related instrument products, as well as protein analysis, LC-MS/MS, characterization analysis, and custom protein services. The company was formerly known as ProteomeTech Inc. and changed its name to Protia Inc. in November 2023. Protia Inc. was founded in 2000 and is headquartered in Seoul, South Korea.
More stocks
- Qualisys Holding AB (publ) (QSYS.ST)
- Namib Minerals Ordinary Shares (NAMM)
- Poled (487580.KQ)
- Nyquest Technology Co Ltd (6494.TWO)
- HYPERION DEFI, INC. (HYPD)
- Carbon-Based Technology Inc. (7719.TWO)
- VirnetX Holding Corp (VHC)
- Precipio, Inc. (PRPO)
- XTI Aerospace, Inc. (XTIA)
- Cytogen Inc (217330.KQ)
- Momentus Inc. (MNTS)
- Eltek Ltd (ELTK)
Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.